230297-18-4

Basic information

• Product Name: Benzenepropanal, 4-fluoro-b-(4-fluorophenyl)-
• CAS NO: 230297-18-4
• Molecular Formula: C15H12F2O
• Molecular Weight: 246.256
• Mol File: 230297-18-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenepropanal, 4-fluoro-b-(4-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepropanal, 4-fluoro-b-(4-fluorophenyl)-(230297-18-4)
• EPA Substance Registry System: Benzenepropanal, 4-fluoro-b-(4-fluorophenyl)-(230297-18-4)

Safety Data

• Hazardous Substances Data: 230297-18-4(Hazardous Substances Data)

Upstream product

• 61668-03-9 1,1'-(but-1-ene-4,4-diyl)bis(4-fluorobenzene) 
• 111448-53-4 3,3-bis(4-fluorophenyl)-1-propanol 
• 342-75-6 3,3-bis(4-fluorophenyl)-propanoic acid 
• 381237-01-0 ethyl 3,3-bis(4-fluorophenyl)propanoate 
• 390-61-4 ethyl 3,3-bis(4'-fluorophenyl)acrylate 
• 345-92-6 4,4'-Difluorobenzophenone 
• 3312-04-7 4-chloro-1,1-bis(4-fluorophenyl)butane 
• 51787-79-2 1,1-bis(-4-fluorophenyl)-4-iodobutane 

Downstream Products

• 1101173-85-6 N-(3,3-bis(4-fluorophenyl)propyl)cyclopropanamine hydrochloride 
• 1101173-81-2 3,3-bis(4-fluorophenyl)-N-(2-(pyridin-2-yl)ethyl)propan-1-amine 
• 1257999-75-9 C₂₉H₂₉ClF₂N₂O 

Relevant articles and documents

Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism

A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essential to finding a compound suitable for oral dosing. Calcimimetic 18 exhibited excellent in vivo potency in a 5/6 nephrectomized rat model and cross-species pharmacokinetics.

Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides

SAR and DMPK studies led to the identification of substituted N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-2-phenylacetamides as potent and orally bioavailable ligands for the human CCR5 chemokine receptor.